儿童腔内型克罗恩病临床复发的危险因素:一项回顾性队列研究
该回顾性队列纳入2009至2019年诊断的639例18岁以下儿童克罗恩病患者,分析临床、内镜、组织学及实验室指标与诱导和维持治疗对复发的影响。过去十年临床复发率下降:2009至2014年诊断者70.9%复发,2015至2019年诊断者49.1%复发(P<0.0001)。女性、口服5-氨基水杨酸、使用免疫调节剂而非肿瘤坏死因子-α抑制剂、活检见肉芽肿、活检嗜酸性粒细胞增多、C反应蛋白和粪钙卫蛋白升高及英夫利西单抗血清水平低与临床复发相关。
要点
- 过去十年儿童克罗恩病临床复发率下降:2009至2014年诊断者70.9% vs 2015至2019年诊断者49.1%(P<0.0001)。
- 女性、口服5-氨基水杨酸、肉芽肿、活检嗜酸性粒细胞增多、C反应蛋白和粪钙卫蛋白升高与复发相关。
- 与肿瘤坏死因子-α抑制剂相比,使用甲氨蝶呤或硫嘌呤及英夫利西单抗血清水平低与复发相关。
核心结论
- 过去十年儿童克罗恩病复发率下降,复发风险与临床、内镜、组织学、实验室变量及治疗策略显著相关。
研究设计与样本
- 回顾性队列研究,纳入2009至2019年诊断的639例18岁以下儿童克罗恩病患者,从病历收集临床、内镜、组织学、实验室数据及诱导和维持治疗,采用生存分析和Cox回归模型评估危险因素对复发的影响。
主要发现
- 临床复发率:2009至2014年诊断者70.9% vs 2015至2019年诊断者49.1%(P<0.0001)。
- 女性与临床复发相关(aHR=1.52,P=0.0007);口服5-氨基水杨酸暴露与临床复发相关(aHR=1.44,P=0.04)。
- 与肿瘤坏死因子-α抑制剂相比,甲氨蝶呤与临床复发相关(aHR=1.73,P=0.003),硫嘌呤与临床复发相关(aHR=1.63,P=0.002)。
- 活检见肉芽肿与临床复发相关(aHR=1.34,P=0.02);活检嗜酸性粒细胞增多与临床复发相关(aHR=1.36,P=0.02)。
- C反应蛋白升高与临床复发相关(aHR=1.01,P<0.0001);粪钙卫蛋白升高与临床复发相关(aHR=1.08,P<0.0001);英夫利西单抗血清水平低与临床复发相关(aHR=2.32,P=0.001)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: There is currently little knowledge on factors associated with the relapse of Crohn's disease (CD) in children. The aims of this study were to describe the risk factors associated with relapse in pediatric CD and the changes in the relapse rate over the past decade. METHODS: Patients younger than 18 years and diagnosed between 2009 and 2019 were included in this retrospective cohort study. Clinical, endoscopic, histological, and laboratory data, as well as induction and maintenance treatments, were collected from the medical records. Survival analyses and Cox regression models were used to assess the impact of these risk factors on relapse. RESULTS: Six hundred thirty-nine patients were included. There was a decrease in the clinical relapse rate over the past decade: 70.9% of the patients diagnosed between 2009 and 2014 relapsed as compared with 49.1% of the patients diagnosed between 2015 and 2019 (P < 0.0001). The following variables were associated with clinical relapse: female sex (adjusted hazard ratio [aHR] = 1.52, P = 0.0007), exposure to oral 5-ASA (aHR = 1.44, P = 0.04), use of immunomodulatory agents compared with tumor necrosis factor-alpha inhibitors (methotrexate aHR = 1.73, P = 0.003; thiopurines aHR = 1.63, P = 0.002), presence of granulomas (aHR = 1.34, P = 0.02) and increased eosinophils on intestinal biopsies (aHR = 1.36, P = 0.02), high levels of C-reactive protein (aHR = 1.01, P < 0.0001) and fecal calprotectin (aHR = 1.08, P < 0.0001), and low serum infliximab levels (aHR = 2.32, P = 0.001). DISCUSSION: Relapse of pediatric CD has decreased in the past decade. The risk of relapse is significantly associated with clinical, endoscopic, histological, and laboratory variables and treatment strategies.
引用
- Sassine S, Djani L, Cambron-Asselin C, et al. Risk Factors of Clinical Relapses in Pediatric Luminal Crohn's Disease: A Retrospective Cohort Study. Am J Gastroenterol. 2022. PMID: 35132979. doi:10.14309/ajg.0000000000001650
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。